Please upgrade your browser.
GlaxoSmithKline is literally putting money on the outcome of a clinical trial now in progress, pitting its pazopanib (Votrient) for advanced renal cell carcinoma against sunitinib (Sutent).
Henry Ford Hospital in Detroit is one of just 17 hospitals across the country and the first in Michigan to use a new treatment that uses electrical pulses to kill cancer cells.
Two Olympia women who lost their husbands to cancer are giving the gift of soup to cancer patients at the Providence Regional Cancer System in Lacey.
People suffering from Kidney cancer / Renal Carcinoma in India can hope for better treatment and have more chances of survival which would be evident from phase III clinical trial carried out by Regrow The only cell Therapy Company in India, in association with Creagene, a Korean based Biotechnology company providing Dendritic Cell Technology.
We conducted a two-stage genome-wide association study of renal cell carcinoma (RCC) in 3,772 affected individuals (cases) and 8,505 controls of European background from 11 studies and followed up 6 SNPs in 3 replication studies of 2,198 cases and 4,918 controls.
This CME activity describes the benefits and limitations of current treatment approaches for patients with advanced renal cell carcinoma (RCC) . . .
Pharmaceutical giant GlaxoSmithKline (GSK) has agreed to offer a 12.5% discount on the list price to the NHS and a possible future rebate following the outcome of a clinical trial comparing the drug to another, sunitinib (Sutent), which is already approved.
Scientists have revealed multiple genetic discoveries that may permit easier diagnosis and disease management for Cowden syndrome patients who are predisposed to breast and kidney cancer .
Patients affected by RCC with VTT and TFI have a higher risk of CSM relative to cases with VTT only.
|Powered by NeonCRM|